

Adult Patient Counselling Checklist – Direct Oral Anticoagulants (DOACs)

Attach addressograph h	ere
Patient name:	
D.O.B:	
NHS number:	

The following checklist should be completed when counselling a patient on a direct oral anticoagulant (DOAC). Please tick the boxes below to indicate that information has been given to the patient. This form should be signed by the patient and the accredited member of staff providing the counselling.

CIRCLE the name of drug/DOAC: generic and brand name				
Edoxaban (brand name Lixiana®)¹	Apixaban (brand name Eliquis®)2			
Rivaroxaban (brand name Xarelto®)3	Dabigatran (brand name Pradaxa®)4			
Dose:	Frequency:	Indication:		
Duration of treatment (depends on indication):				

Counsel	ling points	Tick
	ing from another anticoagulant: Ensure BNSSG Guidance on switching between oral anticoagulants (July 2022) ⁸ is and the patient appropriately counselled on when to stop their current anticoagulant.	
professi	ert card and DOAC patient information leaflet: To be carried with patient at all times and shown to health care onals when new medication is prescribed, or treatment given. Patient details, medication details and treatment must be on the alert card.	
forming	purpose of anticoagulant and indication for Direct Oral Anticoagulant (DOAC): DOACs prevent blood clots from in the blood vessels by making the blood take longer to clot. oral anticoagulants (DOACs) can be used for treatment if patients: already have a blood clot, for example a deep vein thrombosis (DVT) or pulmonary embolism (PE); are at risk of having a blood clot (prevention) for example Atrial Fibrillation (AF) or following surgery to replace a hip or knee.	
Duration	of treatment: confirm length of treatment, this will depend on the indication	
Adminis •	tration/explanation of dose/importance of adherence/missed dose 1,2,3,4,5: Strength, frequency, and timing of doses. It is important that the patient continues to take the anticoagulant as prescribed and does not miss any doses. Patients must not stop taking anticoagulant unless advised to do so by a healthcare professional. Not adhering to anticoagulant treatment may put patients at risk of blood clot, mini stroke or stroke which could be fatal.	
Counsel	for the appropriate medicine ONLY:	
Edoxaba	Swallow whole with water. Take with or without food. Take at roughly the same time each day. For AF: 60mg once a day is the normal dose. A lower dose of 30mg once a day is used for some patients. For DVT or PE: 60mg once a day. A lower dose of 30mg once a day is used for some patients. Missed dose: take as soon as remembered. Do not take more than one tablet in a single day to make up for missed doses. Carry on with the usual dose the following day.	
Apixaba o	Swallow whole with water, take with or without food. If unable to swallow the tablets whole, the tablet may be crushed and mixed with water, apple juice or apple puree	
0	immediately prior to taking. Take at roughly the same time each day. For AF : 5mg twice a day is the normal dose. A lower dose of 2.5mg twice a day is used for some patients.	



- o For **DVT** or **PE**: 10mg twice a day for 7 days then reduce to 5mg twice a day. Following completion of 6 months treatment for DVT or PE, a lower dose of 2.5mg twice a day can be used for prevention of DVT or PE.
- Missed dose: Take the dose immediately then continue with twice daily administration as before. A double dose should not be taken to make up for a missed tablet.

Rivaroxaban (Xarelto)3

- Take with food, swallowed whole with water during mealtimes. If unable to swallow the tablets whole, the tablets may be crushed and mixed with water immediately prior to taking.
- o Take at roughly the same time each day.
- For DVT or PE: 15mg twice a day for 21 days then reduce to 20mg once a day (once daily dose will depend on renal function)
- o For AF: 20mg once a day is the normal dose. A lower dose of 15mg once a day is used for some patients.
- Prevention of VTE in patients undergoing elective hip or knee replacement surgery: 10mg once a day.
- Missed dose ONCE a day: take as soon as remembered. Do not take more than one tablet in a single day. Carry on
 with usual dose the following day.
- Missed dose 15mg TWICE a day: take dose as soon as remembered or take two 15mg tablets at once. Do not take
 more than two tablets in a day. Carry on with usual dose the following day.
- o For **PAD** or **CAD**: **2.5mg twice a day** together with Aspirin 75mg once a day.
- Missed dose 2.5mg TWICE a day: continue with regular dosing at the next scheduled time. Do not double up to make up for missed dose.
- Driving or operating machinery: Rivaroxaban may cause dizziness (common) or fainting (uncommon). You should not drive or operate machinery if you experience any symptoms. See your GP for further advice.

Dabigatran (Pradaxa)4

- Swallow whole with water, take with or without food.
- o Take at roughly the same time each day.
- o Refer to prescription for dose details. Explain dose and number of times a day to patient.
- Capsules to be left in the original containers until ready to take (do not put in dosette/pill boxes)
- Peel off backing foil to expose capsule (do not push through)
- o Do not open capsule as can increase risk of bleeding.
- o Missed dose ONCE a day: continue with regular dose the next day. Do not take more than one dose in a single day.
- Missed dose TWICE a day: if less than 6 hours until next dose then omit and continue with scheduled dose. If more
 than 6 hours until next dose, take at once.

If incorrect dose taken: Obtain advice immediately from pharmacist/GP/NHS Direct (111)/anticoagulant clinic

Repeat prescription: do not run out of tablets or capsules and always have at least a week's supply. Repeat prescriptions can be obtained from GP practice.

Explain common and serious side effects and when to refer:

- The most serious side effect of anticoagulants is bleeding. This can include:
 - nose bleeds blood in vomit or coffee ground vomit blood in sputum blood in urine (red, pink or brown) blood in stools (red or black) severe or spontaneous bruising.
- Seek medical attention if patient develops bleeding side effects.
 - Unexplained bruising inform anticoagulant clinic/GP
 - o Single/self-terminating bleeding episode routine appointment with GP
 - Prolonged/recurrent/severe bleeding/head injury A&E⁵
- If bleeding occurs/patient cuts themselves, apply pressure using a clean, dry dressing. It will take longer for bleeding to stop when taking an anticoagulant.
- Emphasise the need to seek medical attention if involved in major trauma, suffer a significant blow to the head, experience unusual or sudden severe headache, unable to stop bleeding, take too much of the anticoagulant medication.

Interactions with other medicines:

- Always remind prescriber you are taking an anticoagulant and check with pharmacist or doctor to ensure any newly
 prescribed or altered medication is compatible with anticoagulant.
- Always check before buying OTC and/or online medicines, alternative medicines, herbal medicines, certain herbal teas or supplements.
- Do not take aspirin or anti-inflammatory painkillers (e.g., ibuprofen) unless advised by your doctor.

Monitoring and review: Review of treatment and blood tests (kidney function, liver function tests and full blood count) at least once a year or more frequently if required. This will be performed by your GP practice. Patient information booklets on direct oral anticoagulants (DOACs) are available and include a section for recording kidney function - Healthcare staff providing anticoagulation services can access the resources via NHS Forms or Primary Care Support England (PCSE). Regular INR monitoring is not required for DOACs.



Inform all medical staff that they are taking a DOAC: (e.g., GP, nurse, dentist, pharmacist) i.e., prior to surgery. Patients will			
need to be advised if anticoagulant needs to be omitted temporarily.			
Injury: where possible avoid risks of falls/injury. Do not take part in contact sports, minimise risk of harm from manual work.			
Use a soft toothbrush, an electric razor and gloves when gardening.			
Alcohol: No interaction with alcohol but staying within the recommended national guidelines of up to 2 units a day is advised			
– due to the risk of falls with excessive alcohol consumption.			
Pregnancy: It is not recommended to take a DOAC during pregnancy as effect on unborn child is not known. Patients should			
use reliable contraceptives and discuss plans for future pregnancy with their doctor before trying to conceive.			
Breastfeeding: DOACs are not recommended while breast feeding.			
Periods: Patients may experience heavier periods, discuss with GP.			
Give patient the opportunity to ask questions. If unsure seek advice from doctor/pharmacist.			
Queries and Contact details for Anticoagulation Teams:			
Anticoagulant Clinic UHBW: 0117 342 3874			
Anticoagulant Clinic NBT: 0117 414 8405			
Sign and date DOAC counselling checklist with patient/representative:			
Patient Information Leaflet, Alert Card and counselling completed by			
Print Name: Sign:			
Role: Date:/			
To be completed by Patient or Guardian (where appropriate)			
I confirm that I have received and understand the information in the patient information leaflet. If at any point I am			
unsure about the information provided or about any other aspect of my treatment with an oral anticoagulant I will			
seek advice from either my doctor or pharmacist.			
Print Name: Date/			
File checklist in patient's records			

References

- Summary of products characteristics, 2022. Lixiana® (edoxaban) 15mg film coated tablets [Online]. Available from: https://www.medicines.org.uk/emc/product/6907/smpc [Accessed 9 August 2022]
- Summary of products characteristics, 2022. Eliquis® (apixaban) 2.5mg film coated tablets [Online]. Available from: https://www.medicines.org.uk/emc/product/4756/smpc [Accessed 9 August 2022]
- Summary of products characteristics, 2022. Xarelto® (rivaroxaban) 10mg film coated tablets [Online]. Available from: https://www.medicines.org.uk/emc/product/6402/smpc [Accessed 9 August 2022]
- 4. Summary of products characteristics, 2022. *Pradaxa* (*dabigatran*) 110mg hard capsules [Online]. Available from: https://www.medicines.org.uk/emc/product/6229/smpc [Accessed 9 August 2022].
- Primary Care Cardiovascular Society, UKCPA, PCPA, 2022. Anticoagulation for non-valvular atrial fibrillation (NVAF) following NHSE DOAC commissioning recommendations [Online]. Available from: https://pcpa.org.uk/454kgekwj545c87as234lg/FINAL Guidance on prescribing anticoagulation in NVAF July 22 v2(2).pdf [Accessed 9 August 2022].
- Thorne, R., Duane, C., 2020, V3.1. UHBW Clinical Standard Operating Procedure Adult Oral Anticoagulation Counselling. Unpublished. (Reference available on UHBW intranet only).
- 7. Brown, R., Hamer, J., 2021, V 9. *NBT Standard Operating Procedure Oral Anticoagulant Counselling.* Unpublished. (Reference available on NBT intranet only).
- BNSSG ICB & Healthier Together, July 2022. BNSSG Guidance on switching between oral anticoagulants [Online]. Available from: https://remedy.bnssg.icb.nhs.uk/formulary-adult/local-guidelines/2-cardiovascular-system-guidelines/ [Accessed 18 January 2023]
- Healthier Together, July 2022. Primary Care Switch Protocol: To implement the switch from Apixaban or Rivaroxaban to Edoxaban for patients with Non-Valvular Atrial Fibrillation (NVAF) within BNSSG ICB [Online]. Available from: https://remedy.bnssg.icb.nhs.uk/formulary-adult/local-guidelines/2-cardiovascular-system-guidelines/ [Accessed 18 January 2023].

BNSSG Patient Counselling Checklist for DOACs v3.7, Approved by APMOC April 2023, review April 2025 or sooner if there are guideline changes. Produced by ICB Medicines Optimisation Team and adapted with permission from UHBW Adult Oral Anticoagulation Counselling SOP V3.1 2020 and NBT Oral Anticoagulant SOP V9 2021